Immunotherapy After Chemoradiation for Stage 3 Lung Cancer — Consolidation Treatment Explained

Most people with stage 3 lung cancer in India never reach this point, so eligibility is settled before anything else. Consolidation applies to unresectable stage 3 non-small cell lung cancer that has completed concurrent chemoradiation, with a restaging scan showing no progression. Recovery, steroid dose and autoimmune history are then checked.

This is worth saying plainly because stage 3 is where Indian practice and international guidance drift furthest apart. A large proportion of lung cancers here are already stage 4 at diagnosis, and among those that are stage 3, some are operable and some cannot complete concurrent chemoradiation. Consolidation sits at the end of a narrow path. At CION the eligibility question goes to the tumour board with the radiation record and the restaging scan in front of it, before any plan is discussed with the family.

Criteria as set out in NCCN and ESMO non-small cell lung cancer guidance. Regulatory approvals differ between countries, and what may be prescribed in India is governed by CDSCO labelling — confirm with your oncologist which criteria apply to the product being offered to you.

Chemoradiation does the main work. Immunotherapy follows to act on cancer cells that may remain once radiation and chemotherapy have finished. It is deliberately not given at the same time as chest radiation, because both can inflame lung tissue and the combined risk is higher. That is exactly what the word consolidation is describing.

What the consolidation phase is trying to do:

• Act on disease too small to see — a scan that shows no progression is not the same as a scan that proves nothing is left.
• Use the moment radiation creates — radiation damages tumour cells and can make them easier for the immune system to recognise. Consolidation aims to build on that window.
• Keep the lung risk separated in time — radiation pneumonitis and immunotherapy-related pneumonitis are two different problems. Stacking them in the same weeks makes both harder to manage.
• Keep the treatment defined — consolidation has a planned end point, which is unusual in advanced lung cancer and is one of the things patients most want to know.

This is also why the radiation record matters so much at the handover. The dose delivered, the volume of lung that was treated and whether pneumonitis appeared all shape the consolidation decision. If chemoradiation was given elsewhere, bring the full radiation summary rather than only the discharge sheet. Our radiation therapy team and the medical oncology team review that record together, because this decision genuinely sits between the two specialties.

Up to twelve months. Infusions are given as day care, usually every two weeks or every four weeks depending on the schedule chosen, with no overnight stay. Treatment stops earlier if a scan shows progression, or if a side effect makes continuing unsafe. It is not extended past twelve months just because it is being tolerated well.

Schedule and duration as described in NCCN and ESMO guidance for unresectable stage 3 non-small cell lung cancer. Interval and total duration vary with the product selected — ask for your own schedule and planned end date in writing before the first cycle.

Five things, and they usually run in parallel rather than one after another. A restaging scan, a breathing and steroid review, blood and thyroid tests, a tumour board discussion, and the cost and scheme paperwork. The aim is to be ready to start within about six weeks of the last radiation fraction.

• 1 · Restaging scan — booked before radiation ends wherever possible, so the result is available while the six-week window is still open. Coordinated for you at a partner imaging centre.
• 2 · Breathing and steroid review — how much cough or breathlessness is left, whether it is settling, and what steroid dose you are on. This is the single commonest reason consolidation is delayed.
• 3 · Baseline blood work — full blood count, kidney and liver function, and thyroid tests. The thyroid baseline matters because thyroid change is one of the more common immune-related effects later on.
• 4 · Tumour board review — the radiation record, the restaging scan, the biopsy and biomarker report and your fitness are looked at together, by medical and radiation oncology in the same room.
• 5 · Cost and scheme paperwork — insurance pre-authorisation, or Aarogyasri, CGHS, ECHS or ESI processing. Starting this after the scan result rather than before it is a frequent cause of avoidable delay.

If you are the family member coordinating all of this, the most useful thing you can carry is one folder: the radiation summary with dose and dates, the biopsy and biomarker report, the chemotherapy record, the latest scan and the current medication list including steroid doses. That folder is what a second opinion actually runs on.

Breathing above everything else. Your lungs have already had radiation, and checkpoint-inhibitor immunotherapy carries its own risk of lung inflammation. New or worsening breathlessness, a new dry cough, or fever should be reported the same day — not saved for the next scheduled cycle.

Call 1800 202 8726 the same day if any of the following start or get worse. Do not wait for your next appointment, and do not start or stop steroids on your own.

• Breathlessness that is new, or worse than last week — including breathlessness only on climbing stairs or walking to the gate.
• A new dry cough, or a change in a cough you already had.
• Fever, with or without a cough.
• Chest pain or a racing heartbeat — go to the nearest emergency department now, and tell them you are on immunotherapy.
• Loose motions several times a day, or blood or mucus in the stool.
• Deep tiredness, dizziness or feeling faint — these can be the first sign of a thyroid or adrenal problem.

Immune-related effects do not follow the chemotherapy timetable families are used to. They can appear weeks or months into treatment, and occasionally after it has finished. Carry a card or a note saying you are on, or recently completed, immunotherapy, and show it at any hospital you attend — including for something that seems unrelated. This one habit changes how quickly the right treatment gets started.

The infusion itself is the largest line in the bill, and it repeats across roughly a year. Scans, blood tests, day-care charges and any unplanned admission sit on top of it. All figures are indicative, as of August 2026, and move with the product selected, biosimilar availability, the centre and your scheme cover.

What actually drives the total:

• How many cycles you complete — a twelve-month plan is priced per cycle, not as one lump sum, and it can stop earlier.
• The dosing interval — a two-weekly and a four-weekly schedule do not cost the same over a year, even for the same treatment.
• Whether a biosimilar option exists for the product your oncologist selects at the time you start.
• Scans and blood tests — coordinated at partner imaging centres, quoted to you before the appointment.
• Scheme and insurance cover — Aarogyasri, CGHS, ECHS, ESI and private insurance each treat consolidation differently, and ceilings change.

Six questions worth asking before you agree:

• Does my restaging scan show no progression? If it does show progression, consolidation is not the conversation to have.
• Is a PD-L1 threshold being applied to me, and what is my score? Ask for the answer in writing, since this rule differs by product and regulator.
• What is my planned end date? You are entitled to know when this is designed to finish.
• What would make you stop early? Ask what would be counted as progression and what would be counted as an unacceptable side effect.
• What is the expected cost per cycle and for the full plan? Include scans, blood tests and the possibility of an admission.
• What happens if I choose not to have consolidation? Surveillance scans after chemoradiation is a real option, and it should be set out for you rather than treated as giving up.

No page can make this decision for you, and this one is not trying to. What you are owed is the reasoning, the timeline and the cost in language you can repeat at home. That is what a 45-minute consultation and a tumour board review are for.

Three companion pages cover the questions that come up right after this one — how smoking history changes the picture, what happens when the cancer has reached the brain, and the separate question of immunotherapy after surgery rather than after radiation.

• Immunotherapy for Lung Cancer in Smokers vs Non-Smokers — why never-smokers are more likely to carry a targetable alteration, and what that changes about immunotherapy.
• Brain Metastases and Immunotherapy in Lung Cancer — read this if a brain scan has found anything, because it moves the disease out of the stage 3 pathway.
• Adjuvant Immunotherapy After Lung Cancer Surgery — the parallel question for operable disease, which follows surgery instead of chemoradiation.
• Immunotherapy at CION Cancer Clinics — how immunotherapy is planned, given as day care and monitored across our centres.

Ask For the Date, Not Just the Plan

Every immunotherapy plan at CION goes through a tumour board, and the reasoning and the timeline are explained to the family in plain language.